Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) has announced a strategic partnership with PsiloThai, marking its entry into the Asian medical market for psilocybin research. This collaboration follows Thailand's recent regulatory change permitting psilocybin for medical treatment and research. Optimi will supply its GMP-approved natural psilocybin extract capsules for observational studies focusing on patients with addiction and end-of-life distress.
The studies will be conducted in conjunction with Government Hospitals and Rajamangala University, pending formal approval from Thai health authorities. This partnership not only expands Optimi's global footprint but also aligns with Thailand's progressive stance on psychedelic research, potentially paving the way for broader acceptance in Asia.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) ha annunciato una partnership strategica con PsiloThai, segnando il suo ingresso nel mercato medico asiatico per la ricerca sulla psilocibina. Questa collaborazione segue il recente cambiamento normativo della Thailandia che consente l'uso della psilocibina per trattamenti medici e ricerche. Optimi fornirà le sue capsule di estratto di psilocibina naturale approvate GMP per studi osservazionali focalizzati su pazienti con dipendenze e sofferenze terminali.
Gli studi saranno condotti in collaborazione con gli ospedali governativi e l'Università Rajamangala, in attesa dell'approvazione formale delle autorità sanitarie thailandesi. Questa partnership non solo amplia la presenza globale di Optimi, ma si allinea anche alla posizione progressista della Thailandia sulla ricerca psichedelica, aprendo potenzialmente la strada a un'accettazione più ampia in Asia.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) ha anunciado una asociación estratégica con PsiloThai, marcando su entrada en el mercado médico asiático para la investigación de la psilocibina. Esta colaboración sigue al reciente cambio regulatorio en Tailandia que permite el uso de la psilocibina para tratamientos médicos e investigación. Optimi proporcionará sus cápsulas de extracto de psilocibina natural aprobadas por GMP para estudios observacionales centrados en pacientes con adicciones y angustia al final de la vida.
Los estudios se llevarán a cabo en conjunto con hospitales gubernamentales y la Universidad Rajamangala, a la espera de la aprobación formal de las autoridades sanitarias tailandesas. Esta asociación no solo expande la huella global de Optimi, sino que también se alinea con la postura progresista de Tailandia sobre la investigación psicodélica, allanando el camino para una aceptación más amplia en Asia.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF)는 PsiloThai와 전략적 파트너십을 발표하여 실로시빈 연구를 위한 아시아 의료 시장에 진입했습니다. 이 협력은 태국의 최근 규제 변화로 인해 실로시빈이 의료 치료 및 연구에 사용될 수 있게 된 것에 따른 것입니다. Optimi는 GMP 승인된 자연 실로시빈 추출 캡슐을 제공하여 중독 및 말기 고통을 앓고 있는 환자들을 위한 관찰 연구에 사용될 것입니다.
이 연구들은 정부 병원 및 라차망갈라 대학교와 함께 진행될 예정이며, 태국 보건당국의 공식 승인을 기다리고 있습니다. 이 파트너십은 Optimi의 글로벌 입지를 확장할 뿐만 아니라 태국의 진보적인 환각제 연구에 대한 입장과도 일치하여 아시아 전역에서의 폭넓은 수용 가능성을 열어줍니다.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) a annoncé un partenariat stratégique avec PsiloThai, marquant son entrée sur le marché médical asiatique pour la recherche sur la psilocybine. Cette collaboration fait suite au récent changement réglementaire en Thaïlande qui autorise l'utilisation de la psilocybine pour les traitements médicaux et la recherche. Optimi fournira ses capsules d'extrait de psilocybine naturel approuvées par la GMP pour des études d'observation axées sur les patients souffrant de dépendance et d'angoisse en fin de vie.
Les études seront menées en collaboration avec des hôpitaux gouvernementaux et l'Université Rajamangala, en attente de l'approbation formelle des autorités sanitaires thaïlandaises. Ce partenariat non seulement accroît la présence mondiale d'Optimi, mais s'aligne également sur la position progressiste de la Thaïlande concernant la recherche psychédélique, ouvrant potentiellement la voie à une acceptation plus large en Asie.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) hat eine strategische Partnerschaft mit PsiloThai angekündigt, die den Eintritt in den asiatischen medizinischen Markt für Psilocybin-Forschung markiert. Diese Zusammenarbeit erfolgt im Anschluss an die jüngste regulatorische Änderung in Thailand, die Psilocybin für medizinische Behandlungen und Forschungen erlaubt. Optimi wird seine GMP-zugelassenen natürlichen Psilocybin-Extraktkapseln für Beobachtungsstudien bereitstellen, die sich auf Patienten mit Suchtproblemen und leidensdruck am Lebensende konzentrieren.
Die Studien werden in Zusammenarbeit mit Regierungskrankenhäusern und der Rajamangala-Universität durchgeführt, wobei die offizielle Genehmigung von den thailändischen Gesundheitsbehörden noch aussteht. Diese Partnerschaft erweitert nicht nur die globale Präsenz von Optimi, sondern entspricht auch Thailands progressiver Haltung zur psychedelischen Forschung, was möglicherweise den Weg für eine breitere Akzeptanz in Asien ebnet.
- First psychedelics manufacturer to enter Asian medical market for psilocybin research
- Strategic partnership with PsiloThai, a leading patient advocacy group in Thailand
- Expansion into new market following Thailand's regulatory change permitting psilocybin for medical use
- Potential for broader market acceptance and use of psychedelics in medical treatments throughout Asia
- Similar supply agreement already in place with Mind Medicine Australia, showcasing global expansion
- Studies are pending formal approval and permitting from Thai health authorities
- Initial term of social media marketing engagement with Fairfax Partners Inc. costs $43,900 for three months
Observational studies to focus on patients with addiction and end-of-life distress pending formal approval and permitting from Thai health authorities
Vancouver, British Columbia--(Newsfile Corp. - July 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce a strategic supply partnership and Letter of Intent with PsiloThai, a leading patient advocacy group registered in Thailand. This agreement marks a significant milestone as Optimi becomes the first psychedelics manufacturer to seek approval for its products to enter the Asian medical market for use in observational studies in patients with addiction and end-of-life distress.
This significant step follows Thailand's Ministry of Public Health's recent regulatory change to permit psilocybin for medical treatment, research, and clinical trials. Permission for the use of the two Category 5 drugs was announced in a directive published earlier this year. The directive, referring to psilocybin mushrooms and signed by Public Health Minister Cholnan Srikaew, took effect on April 26, 2024.
Bill Ciprick, CEO of Optimi, expressed enthusiasm about this new venture: "Optimi is excited to validate our GMP natural psilocybin extract capsules further with the support of PsiloThai. This partnership not only opens new avenues for research but also strengthens our commitment to advancing mental health treatments around the world. We are honored to be embarking on this first-of-its-kind journey in Thailand."
Charlie Solares, Founder of PsiloThai, commented, "This collaboration with Optimi provides a unique opportunity to explore the therapeutic potential of psilocybin in treating complex conditions such as addiction and end-of-life distress. We are optimistic about the positive outcomes these studies can yield. Partnering directly with a Health Canada licensed entity like Optimi allows us to leverage their expertise in cultivation, compliance, and GMP drug manufacturing to ensure the highest quality and standards for our patients."
The observational studies will help patients currently in hospital care and will be conducted in conjunction with Government Hospitals and Rajamangala University. Optimi will work closely with PsiloThai to secure the necessary import certificates to fulfill the supply requirements in the coming months, with the studies officially commencing upon formal approval from Thai Health Authorities.
Key Benefits and Impact:
- Enhanced Research Opportunities: The partnership with PsiloThai allows Optimi to tap into the extensive research capabilities of Thai academic institutions, healthcare facilities, and patient base.
- Broader Reach: Entering the Asian market enables Optimi to expand its footprint and bring its innovative treatments to a larger and more diverse population.
- Regulatory Advancements: The Kingdom of Thailand's progressive stance on allowing psilocybin use for research and trials sets a precedent for other nations, potentially paving the way for broader acceptance and use of psychedelics in medical treatments throughout Asia.
Optimi currently has a similar supply agreement in place with Mind Medicine Australia, an internationally renowned patient advocacy group that successfully advocated for the Therapeutic Goods Administration (TGA) to reclassify MDMA and psilocybin from Schedule 9 to Schedule 8 in 2023. Last month, Health Canada approved three export permits, marking Optimi's commercial entry into Australia with its GMP psychedelic medicines for eligible patients suffering from PTSD and Treatment-Resistant Depression.
The Company also announces it has engaged Fairfax Partners Inc. ("Fairfax"), an arm's length party, to provide social media marketing. The initial term is for three months for a fee of
For more information, please contact:
OPTIMI HEALTH CORP.
Bill Ciprick, CEO
Telephone: (778) 761-4551
For media inquiries, please contact:
Andrea Mestrovic
Andrea@weareverypolite.com
For investor inquiries, please contact:
Michael Kydd
investors@optimihealth.ca
For more information, please visit Optimi Health.
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN)
Optimi is the only psychedelics pharmaceutical manufacturer in Canada with both a Controlled Drugs and Substances Dealer's Licence and a Drug Establishment Licence (DEL). Specializing in controlled substances such as botanical psilocybin and MDMA, Optimi is dedicated to supplying safe, top-tier GMP-grade products and API to researchers, drug developers, and authorized patients in markets across the world.
Optimi's leadership is reinforced by state-of-the-art, GMP-compliant cultivation, formulation, and analytical facilities, purpose-built to develop proprietary formulations that meet the highest standards of quality and responsible sourcing. Located in Princeton, British Columbia, the two facilities total 20,000 square feet where all products are grown and manufactured in-house under strict GACP and GMP conditions, ensuring unparalleled quality and reliability. The Company is committed to being the most trusted and compassionate supplier of safe psychedelic drug candidates worldwide.
FORWARD‐LOOKING STATEMENTS:
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to Optimi's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/217369
FAQ
What is the significance of Optimi Health's partnership with PsiloThai for stock OPTHF?
What specific research will Optimi Health (OPTHF) be conducting in Thailand?
How does Thailand's recent regulatory change affect Optimi Health's (OPTHF) operations?
What other international markets has Optimi Health (OPTHF) entered recently?
